AIDS Research and Human Retroviruses · 2007 · 18 citations · 11 references
Life SciencesPharmacotherapyMolecular VirologyPharmacogeneticsPharmacogenomicsAntiretroviral TherapyAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyInfectious Disease PharmacogenomicsPharmacogenomics In ChildrenCombination Drug TherapyDrug Resistance MutationsFirst-line Antiretroviral RegimensGenetic PolymorphismsMolecular Drug ResistanceNon-nucleoside InhibitorsNon-nucleoside Reverse Transcriptase InhibitorsNucleoside Reverse Transcriptase Inhibitors
Access to antiretroviral therapy has expanded in many developing countries, including India. The standard first-line regimens consist of a combination of two nucleoside reverse transcriptase inhibitors and a nonnucleoside reverse transcriptase inhibitor, in a fixed drug combination. Data regarding resistance to these drugs are scarce, especially in children. We evaluated the pattern of polymorphism and potential drug resistance mutations (DRMs) in HIV-1 isolates from 48 children naive to antiretroviral therapy attending the outpatient clinics of the Tuberculosis Research Center in Chennai. The samples were subjected to genotyping of reverse transcriptase (RT) and protease genes. All the samples showed significant polymorphisms in both RT and protease genes, but none had major DRMs. The currently recommended generic first-line antiretroviral drug combination is an appropriate treatment strategy for HIV-1-infected children in India.
11
Sarah Palmer, Valerie F. Boltz, Neil Martinson et al. · Proceedings of the National Academy of Sciences · 2006 · 148 citations · Full text
Nagadenahalli B. Siddappa, Prashanta Kumar Dash, Anita Mahadevan et al. · Journal of Clinical Microbiology · 2004 · 79 citations · Full text
Alaka Deshpande, Patrícia Recordon-Pinson, Ranjana Deshmukh et al. · AIDS Research and Human Retroviruses · 2004 · 57 citations
Marie‐Laure Chaix, Fran ois Rouet, Kouakou Alain Kouakoussui et al. · The Pediatric Infectious Disease Journal · 2005 · 56 citations